We Underwrote the Underwriter

Cigna trades 55% below what our model says it is worth. An insurer would never quote a policy from a number that seductive without reading the exclusions, inspecting the claims history, and asking what could go catastrophically wrong. So neither did we—and the file contains a fair, intelligent case for disagreeing with our verdict.

Cigna has built an empire by answering one question:

What is this risk actually worth?

Hand its actuaries a patient, a prescription, or a million-member health plan, and they do not stop at the number printed on the application. They search behind it. They estimate probabilities, identify hidden liabilities, model adverse outcomes, and decide how much uncertainty must be charged into the premium.

That is the profession.

So before writing a single bullish sentence about a company that prices risk for a living, we owed ourselves an obvious question:

If Cigna would never underwrite a policy from a raw number without examining what stands behind it, why should we underwrite its stock that way?

The raw number is remarkable.

Certainly, Master. Here is a clean Markdown table ready to drop into the story:

Our model estimates fair value at $636.30. The shares trade at $284.64. That is a 55.3% discount—the sort of number that, printed on a billboard, could make a value investor take the next exit and start asking what the market knows that the model does not.

We took the exit.

Then we opened the file.

The Case for Writing the Check

Let us begin with the bullish case, because it is real, substantial, and deserves better than being constructed as a strawman for the bears to knock over later.

Cigna has raised its earnings guidance twice this year—first to at least $30.25 per share, then to at least $30.45. That matters in a healthcare sector where several competitors have spent 2026 lowering expectations and explaining why yesterday’s numbers no longer apply.

Evernorth, Cigna’s pharmacy-benefit and health-services platform, has become the company’s primary economic engine. Its Specialty and Care operation recently delivered 22% earnings growth. This is not a stagnant insurer disguising itself with fashionable language. It is an increasingly diversified health-services enterprise with enormous scale, deep client relationships, and a growing profit center outside traditional insurance underwriting.

Cigna is also simplifying itself.

The company sold its Medicare Advantage business in March 2025 for approximately $3.7 billion. Its exit from the Individual and Family Plans business is expected to follow in January 2027. These moves reduce exposure to businesses management evidently believes offer less attractive risk-adjusted returns than Evernorth and the company’s commercial franchise.

Then there is the leadership transition.

David Cordani moved from chief executive to executive chair in July 2026. His successor, Brian Evanko, is not an outsider arriving with a consulting deck and a list of people to fire. He is a nearly three-decade Cigna veteran who has already served as chief financial officer and led the company’s healthcare business.

If corporate succession can ever be described as controlled, this is what controlled looks like.

Put the pieces together:

• Earnings guidance raised twice.
• A faster-growing services platform.
• A simplified portfolio.
• A deeply experienced internal successor.
• Shares trading at less than half our estimated value.

If the analysis ended here, the conclusion would practically sign itself.

A great deal of stock analysis does end here.

Underwriting cannot.

The Part of the File Marked “Do Not Skip”

A 55% discount in a large, profitable, widely followed company is rarely a gift left unattended on the sidewalk. The market may be wrong, but it is usually worried about something specific.

In Cigna’s case, the concerns reach directly into the business now generating most of the company’s growth.

None of this describes a company on fire.

It describes something harder to value: a strong company whose most important engine sits inside one of the most politically exposed business models in American healthcare.

That difference matters. Fires are obvious. Regulatory erosion is quieter.

Evernorth: Engine, Moat—and Target

Pharmacy-benefit managers occupy the complicated territory between drug manufacturers, insurers, pharmacies, employers, and patients. Their scale gives them tremendous negotiating power. They determine formularies, process claims, negotiate rebates, manage specialty drugs, and influence what millions of people pay for medicine.

That complexity produces economic value.

It also produces suspicion.

Spread pricing, manufacturer rebates, pharmacy reimbursements, formulary placement, and PBM compensation have drawn sustained criticism from regulators and lawmakers across party lines. The central accusation is that a system designed to negotiate lower drug costs has become too opaque for patients, employers, and even plan sponsors to determine where the savings actually go.

Cigna’s February 2026 settlement involving Express Scripts places binding restrictions and a ten-year monitoring period around practices connected to that model.

A decade is not a slap on the wrist. It is a regulatory roommate.

This does not mean Express Scripts is broken. It means the durability of its future economics can no longer be estimated entirely from its historical economics. If the rules governing rebates and spread pricing change, yesterday’s margins may not describe tomorrow’s earning power.

That uncertainty is not fatal.

But it belongs in the premium.

Cigna Has Already Started Rewriting the Policy

Buried inside the regulatory concern is one of the more interesting pieces of the bull case.

Cigna plans to introduce a “signature” rebate-free pricing model within its own fully insured health plans in 2027, followed by a broader rollout in 2028.

In effect, the company is attempting to insure itself against the very risk we are underwriting.

That move can be read two ways.

The skeptical interpretation is that Cigna recognizes the traditional rebate structure may not survive unchanged and is repositioning before regulators force a more painful transition.

The favorable interpretation is that management sees the direction of policy early, has the scale to adapt, and may emerge with a more transparent model before slower competitors are ready.

Both interpretations may be true.

Good strategy often begins as an admission that the old strategy has an expiration date.

The question is whether Cigna can replace the economics before the old ones are regulated away.

The Algorithm in the Examination Room

The PxDx litigation raises a different concern.

The allegation is not simply that Cigna denied healthcare claims. Every insurer denies claims; coverage decisions are part of the business. The dispute concerns whether an automated system enabled physicians to reject large volumes of claims without sufficiently individualized review of the patients’ medical records.

The case remains unresolved. Allegations are not findings.

But the issue reaches beyond one lawsuit.

Algorithms can make healthcare administration faster, cheaper, and more consistent. They can also scale poor judgment with extraordinary efficiency. A flawed human process harms people one decision at a time. A flawed automated process can reproduce the same decision thousands of times before lunch.

Cigna may ultimately demonstrate that appropriate clinical oversight existed. It may modify the system, settle the litigation, prevail in court, or face additional scrutiny.

We do not know.

An underwriter does not require certainty that a claim will be paid before pricing the risk. The possibility, severity, and uncertainty are enough.

The $710 Million Question

Then there is first-half operating cash flow: $710 million.

Placed beside roughly $8 billion in guided annual adjusted earnings power, that number deserves attention.

There may be a reasonable explanation. Healthcare companies can experience substantial working-capital movements, timing differences, receivable changes, settlement activity, and seasonal cash-flow patterns. One half-year cash-flow figure should not be treated as a complete economic diagnosis.

But neither should it be waved away because adjusted earnings look better.

Adjusted earnings are management’s translation of the business.

Cash is the language the balance sheet speaks when nobody is presenting slides.

Until the gap is fully reconciled, it lowers our certainty—not necessarily our estimate of Cigna’s long-term value, but our confidence in how smoothly that value will reach shareholders.

Pricing the Policy

This is where a striking valuation becomes an investment decision.

Our framework separates the apparent discount from the confidence we place in capturing it.

The raw valuation says Cigna is extraordinarily cheap.

The underwriting adjustment says we should not trust every dollar of that apparent discount equally.

The calculation is straightforward:

Our threshold for committing new capital is 25%.

Cigna misses by one-tenth of one percentage point.

That is not a triumphant rejection. It is barely a declined application.

The Most Honest Part: You Could Reasonably Buy It

Investment writing often treats disagreement as evidence that someone failed to understand the facts.

That is not what is happening here.

There is a legitimate, informed case for buying Cigna today—even after reading every page in this file.

If you believe the rebate-free model will materially reduce regulatory risk before regulation becomes more disruptive; if you regard Evanko’s long institutional experience as continuity rather than uncertainty; if you believe twice-raised guidance is the loudest signal in the entire analysis; and if you see the weak first-half cash flow as timing rather than deterioration, then acting on a 55% raw discount is entirely defensible.

You would not be ignoring the risk.

You would be pricing it differently.

That distinction is important. Different insurers write different books. Some avoid hurricanes. Others specialize in coastal property because the premiums are high and they believe their models understand the storm better than the market does.

Cigna may be that kind of opportunity: visible danger, unusually attractive pricing, and a potential return large enough to compensate investors willing to accept the uncertainty.

A reasonable investor could sign this policy.

We are not doing so today.

Why 0.1 Percentage Point Still Matters

A threshold is not an oracle.

There is no meaningful economic difference between a conviction-adjusted MOS of 24.9% and 25.0%. The universe did not place a velvet rope at precisely 25%.

But a portfolio rule does not exist because the boundary is metaphysically perfect. It exists because judgment becomes dangerously flexible when money and excitement occupy the same room.

If we waive the threshold whenever a stock misses by only 0.1%, then 24.9% becomes the new threshold. Later, 24.5% will look close enough to 24.9%. Eventually, the rule becomes a historical anecdote about discipline we once intended to have.

The line may be somewhat arbitrary.

Obeying it is not.

Where We Land

Certainly, Master. Here is a clean Markdown table ready to drop into the story:

Cigna moves onto the watchlist, not the buy list.

That does not mean the stock is overpriced. Our own model says the opposite.

It does not mean the business is broken. Twice-raised guidance says the opposite.

It means we are unwilling to insure the full face value of a 55% apparent discount while a ten-year regulatory-monitoring period begins around the company’s dominant growth engine, an algorithmic-denial lawsuit remains unresolved, customer count is contracting, cash conversion requires explanation, and a new CEO is taking control.

We want one more dated piece of evidence: Cigna’s September Investor Day.

It will also be Brian Evanko’s first major strategic presentation as chief executive. Management should have an opportunity to explain the economics of the rebate-free model, the durability of Evernorth’s margins, customer trends, capital allocation, cash conversion, and the company’s post-Medicare identity.

If the answers are substantive, the certainty score may improve.

If the answers amount to attractive slides wrapped around familiar ambiguities, we will have avoided paying the premium before reading the exclusions.

Either outcome will teach us something.

The Underwriter’s Verdict

Any stock can show you a large number.

The worthwhile question is what that number is compensating you to endure.

Cigna offers a 55.3% raw discount because the market is not valuing growing earnings in isolation. It is pricing political hostility toward PBMs, restrictions on Express Scripts, uncertainty around automated claims review, declining customer counts, uneven cash conversion, and the possibility that today’s most profitable practices may not remain tomorrow’s permissible ones.

Our valuation sees $636.30 per share.

Our underwriting discipline adds a deductible.

After pricing the uncertainty, the actionable margin of safety falls to 24.9%—one-tenth of a point below our line.

Another investor may examine the same evidence, assign a little more credit to management, and buy today. That would not make the investor careless. It would mean they are willing to write a different kind of policy.

As for us, the application remains open.

We have not rejected the company.

We have not dismissed the discount.

We have simply reached the most difficult sentence in underwriting:

The risk may be worth taking. It is not yet worth taking for us.

We are watching the file.

We have not signed our name.

This is not financial advice. All opinions expressed are the author’s alone. As of this report, the author holds no position in The Cigna Group. Figures are based on Cigna’s Q2 2026 Form 10-Q and earnings materials, SEC filings concerning leadership and ownership, the February 2026 FTC–Express Scripts settlement, and cited legal and financial reporting. Readers should conduct their own due diligence.